Claims
- 1. A blood processing system comprising a blood component product harvested from the blood drawn from an individual, a container sized to receive the blood component product, and a device communicating with the container to remove cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators from the blood component product.
- 2. A system according to claim 1wherein the blood component product includes a red blood cell component.
- 3. A system according to claim 1wherein the blood component product includes a platelet component.
- 4. A system according to claim 1wherein the blood component product includes a white blood cell component.
- 5. A system according to claim 1wherein the blood component product includes a plasma component.
- 6. A system according to claim 1wherein the device includes an adsorption medium to remove cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators.
- 7. A system according to claim 6wherein the adsorption medium is characterized by a Biocompatibility Index of not greater than 14.
- 8. A system according to claim 7wherein the Biocompatibility Index is not greater than 7.
- 9. A system according to claim 1 or 2wherein the device includes an adsorption medium to remove cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators, the adsorption medium comprising a polymeric material.
- 10. A system according to claim 9wherein the polymeric material comprises particles prepared by polymerization or copolymerization of a monomer selected from a group consisting of styrene, ethylstyrene, α-methylstyrene, divinylbenzene, di isopropenyl benzene, trivinylbenzene, and alkyl methacrylate.
- 11. A system according to claim 9wherein the polymeric material comprises particles formed from crosslinked polystyrene-type resins having a surface modified to minimize activation of blood complement system.
- 12. A system according to claim 9wherein the polymeric material comprises particles formed from a porous hydrophobic divinylbenzene copolymer having a surface modified to include surface exposed functional groups selected from the group of polymers of 2-hydroxyethyl methacrylate, N-vinylpyrrolidine, N-vinylcaprolactame and N-acrylamide.
- 13. A system according to claim 9wherein the polymeric material comprises particles formed by polymerization of aromatic divinyl compounds or their copolymerization with aromatic monovinyl compounds in the presence of porogens or mixtures of porogens with properties close to those of θ-solvents.
- 14. A system for collecting a blood component product comprising
means for processing the blood drawn from an individual into a blood component product, a storage container, means for collecting the blood component product in the storage container, and means for removing cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators from the blood component product before, during, or after its collection in the storage container.
- 15. A system according to claim 14wherein the blood component product includes a red blood cell component.
- 16. A system according to claim 14wherein the blood component product includes a platelet component.
- 17. A system according to claim 14wherein the blood component product includes a white blood cell component.
- 18. A system according to claim 14wherein the blood component product includes a plasma component.
- 19. A system according to claim 14wherein the means for removing cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators includes an adsorption medium to remove cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators.
- 20. A system according to claim 19wherein the adsorption medium is characterized by a Biocompatibility Index of not greater than 14.
- 21. A system according to claim 20wherein the Biocompatibility Index is not greater than 7.
- 22. A system according to claim 14wherein the device includes an adsorption medium to remove cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators, the adsorption medium comprising a polymeric material.
- 23. A system according to claim 22wherein the polymeric material comprises particles prepared by polymerization or copolymerization of a monomer selected from a group consisting of styrene, ethylstyrene, α-methylstyrene, divinylbenzene, di isopropenyl benzene, trivinylbenzene, and alkyl methacrylate.
- 24. A system according to claim 22wherein the polymeric material comprises particles formed from crosslinked polystyrene-type resins having a surface modified to minimize activation of blood complement system.
- 25. A system according to claim 22wherein the polymeric material comprises particles formed from a porous hydrophobic divinylbenzene copolymer having a surface modified to include surface exposed functional groups selected from the group of polymers of 2-hydroxyethyl methacrylate, N-vinylpyrrolidine, N-vinylcaprolactame and N-acrylamide.
- 26. A system according to claim 22wherein the polymeric material comprises particles formed by polymerization of aromatic divinyl compounds or their copolymerization with aromatic monovinyl compounds in the presence of porogens or mixtures of porogens with properties close to those of e-solvents.
- 27. A method for collecting a blood component product comprising the steps of
processing the blood drawn from an individual into a blood component product, collecting the blood component product in a storage container, and removing cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators from the blood component product before, during, or after its collection in the storage container.
- 28. A method according to claim 27wherein the blood component product includes a red blood cell component.
- 29. A method according to claim 27wherein the blood component product includes a platelet component.
- 30. A method according to claim 27wherein the blood component product includes a white blood cell component.
- 31. A method according to claim 27wherein the blood component product includes a plasma component.
- 32. A method according to claim 27wherein the removing step includes use of an adsorption medium to remove cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators.
- 33. A method according to claim 32wherein the adsorption medium comprises a polymeric material.
- 34. A method according to claim 33wherein the polymeric material comprises particles prepared by polymerization or copolymerization of a monomer selected from a group consisting of styrene, ethylstyrene, α-methylstyrene, divinylbenzene, di isopropenyl benzene, trivinylbenzene, and alkyl methacrylate.
- 35. A method according to claim 33wherein the polymeric material comprises particles formed from crosslinked polystyrene-type resins having a surface modified to minimize activation of blood complement system.
- 36. A method according to claim 33wherein the polymeric material comprises particles formed from a porous hydrophobic divinylbenzene copolymer having a surface modified to include surface exposed functional groups selected from the group of polymers of 2-hydroxyethyl methacrylate, N-vinylpyrrolidine, N-vinylcaprolactame and N-acrylamide.
- 37. A method according to claim 33wherein the polymeric material comprises particles formed by polymerization of aromatic divinyl compounds or their copolymerization with aromatic monovinyl compounds in the presence of porogens or mixtures of porogens with properties close to those of θ-solvents.
RELATED APPLICATIONS
[0001] This application is a continuation-in-part of co-pending U.S. patent application Ser. No. 09/832,159, filed Apr. 10, 2001, and entitled “System for Treating Patient with Bacterial Infections,” which is incorporated herein by reference. This application is also a continuation-in-part of co-pending U.S. patent application Ser. No. 09/829,252, filed Apr. 10, 2001, and entitled “Method of Treating Patient with Bacterial Infections,” which is also incorporated herein by reference. This application claims, under 35 U.S.C. §120, the benefit of the filing date of copending U.S. patent application Ser. No. 09/294,224, filed Apr. 19, 1999, and entitled “Method for Removing Beta-2 Microglobulin from Blood,” which is a continuation-in-part of U.S. patent application Ser. No. 08/902,727, filed Jul. 30, 1997 (now U.S. Pat. No. 5,904,663).
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09832159 |
Apr 2001 |
US |
Child |
10032802 |
Dec 2001 |
US |
Parent |
09829252 |
Apr 2001 |
US |
Child |
10032802 |
Dec 2001 |
US |